Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.66 |
| ▸ | SRC | P12931 | 7/20 | 0.53 |
| ▸ | GAK | O14976 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 11/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.43 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25491262 | 0.80 | FGFR4 (0.52) | FGFR4 | |
| SCHEMBL21611000 | 0.79 | DYRK1A (1.00) | DYRK1ASRCGAKEGFRFGFR4 | |
| SCHEMBL4580932 | 0.79 | MAPK9 (0.53) | DYRK1ASRC | |
| SCHEMBL16668807 | 0.76 | NCF1 (0.46) | FGFR4 | |
| SCHEMBL16671033 | 0.74 | FGFR4 (0.60) | FGFR4 | |
| SCHEMBL28608878 | 0.73 | DYRK1A (0.67) | DYRK1ASRCGAKEGFRRIPK2 | |
| SCHEMBL16331603 | 0.72 | DYRK1A (0.44) | DYRK1ASRCGAKEGFRRIPK2 | |
| SCHEMBL4581593 | 0.71 | DYRK1A (0.48) | DYRK1ASRCGAKFGFR4RIPK2 | |
| SCHEMBL16668784 | 0.71 | FGFR4 (0.56) | FGFR4 | |
| SCHEMBL21610989 | 0.70 | DYRK1A (0.84) | DYRK1ASRCGAKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | claimed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2008024963-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | RB1, MKI67, CCNB1 | DYRK1A 2145/4885SRC 1098/4885GAK 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.